Patents by Inventor Mark L. MICHAELS

Mark L. MICHAELS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ErbB4 BUT NOT AGAINST ErbB3
    Publication number: 20220402985
    Abstract: The present invention relates to engineered neuregulin-1 variants that selectively activate ErbB4 receptors but do not activate ErbB3 receptors. The invention also provides methods for using such variants to treat heart failure.
    Type: Application
    Filed: June 9, 2022
    Publication date: December 22, 2022
    Inventors: Darren L. BATES, Zhi LIU, TaeWeon LEE, Mark L. MICHAELS, Zhulun WANG
  • METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
    Publication number: 20210087286
    Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
    Type: Application
    Filed: June 20, 2018
    Publication date: March 25, 2021
    Applicant: AMGEN INC.
    Inventors: Darren L. BATES, Donghui SHI, David J. LLOYD, Pavel BONDARENKO, Mark L. MICHAELS, Todd HAGER, Xiaoshan MIN, Aiko UMEDA, Irwin CHEN, Zhulun WANG
  • HETERODIMERIC BISPECIFIC ANTIBODIES
    Publication number: 20140308285
    Abstract: Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 16, 2014
    Applicant: Amgen Inc.
    Inventors: Wei YAN, Martin J. PENTONY, Luis G. BORGES, Mark L. MICHAELS
  • BISPECIFIC-Fc MOLECULES
    Publication number: 20140302037
    Abstract: Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 9, 2014
    Applicant: Amgen Inc.
    Inventors: Luis G. BORGES, Patrick A. BAEUERLE, Wei YAN, Mark L. MICHAELS